Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

No, Donald Trump was not the focus of attention this week, even though the US president invited people to a parade to ...

Recursion Pharmaceuticals ( RXRX -5.13%) is not the most famous artificial intelligence (AI) stock on the market, but the ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

Healthcare Summit 2025 hosted by IISc attracts 500 global leaders to focus on future of sector: Our Bureau, Bengaluru Monday, June 16, 2025, 14:45 Hrs [IST] Indian Institute of Sc ...

Health workers have long relied on Body Mass Index to gauge whether people are within a healthy weight range. Now, top researchers have made the case for a new way to understand and diagnose obesity.